The price of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) closed at $4.61 in the last session, down -1.28% from day before closing price of $4.67. On the day, 1979399 shares were traded.
Ratios:
We take a closer look at BCRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.12 and its Current Ratio is at 3.31.
On September 18, 2023, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $9 to $10.
Jefferies Upgraded its Hold to Buy on August 04, 2023, while the target price for the stock was maintained at $11.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 15 ’23 when SANDERS MACHELLE sold 4,000 shares for $7.98 per share. The transaction valued at 31,920 led to the insider holds 25,611 shares of the business.
Hutson Nancy J sold 12,866 shares of BCRX for $103,443 on Jun 14 ’23. The Director now owns 81,818 shares after completing the transaction at $8.04 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.87.
Stock Price History:
Over the past 52 weeks, BCRX has reached a high of $9.06, while it has fallen to a 52-week low of $4.45.
Shares Statistics:
A total of 205.77M shares are outstanding, with a floating share count of 198.56M. Insiders hold about 3.68% of the company’s shares, while institutions hold 84.65% stake in the company.
Earnings Estimates
The company has 11 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.28, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.06 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$0.26 and -$0.84 for the fiscal current year, implying an average EPS of -$0.62. EPS for the following year is -$0.34, with 10 analysts recommending between -$0.11 and -$0.76.
Revenue Estimates
According to 10 analysts, the current quarter’s revenue is expected to be $86.01M. It ranges from a high estimate of $87.56M to a low estimate of $83.53M. As of the current estimate, Biocryst Pharmaceuticals Inc.’s year-ago sales were $68.78M, an estimated increase of 25.10% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $98.36M, an increase of 19.20% less than the figure of $25.10% in the same quarter last year. There is a high estimate of $101.53M for the next quarter, whereas the lowest estimate is $96M.
A total of 11 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $406.75M, while the lowest revenue estimate was $382.08M, resulting in an average revenue estimate of $395.92M. In the same quarter a year ago, actual revenue was $331.41M, up 19.50% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $475.7M in the next fiscal year. The high estimate is $510.06M and the low estimate is $398M. The average revenue growth estimate for next year is up 20.20% from the average revenue estimate for this year.
